Our research group has found that genome-wide DNA methylation status is a predictor of sensitivity to anti-estimated glomerular filtration rate (EGFR) antibody drugs, which are standard treatments for unresectable advanced/recurrent CRC (hereafter referred to as advanced/recurrent CRC), and also a predictor of prognosis. Here, EGFR is linked to colorectal carcinoma.